fenebrutinib (GDC-0853) - Roche
Xolair (omalizumab) - Roche, Novartis
Nucala (mepolizumab) - GSK
ligelizumab (QGE 031) - Novartis
antolimab (AK002) - Allakos
Dupixent (dupilumab) - Sanofi, Regeneron
Cinqair (reslizumab) - Merck (MSD), UCB, Teva
Fasenra (benralizumab) - AstraZeneca
UB-221 - United BioPharma
remibrutinib (LOU064) - Novartis
New treatments for chronic urticaria. (PubMed, Ann Allergy Asthma Immunol) - Aug 26, 2019 - "Novel and better treatments for CU are very much needed. Some are in clinical trials already, and additional ones should be developed, making use of the many promising targets recently identified and characterized." 
Journal • Review • Dermatology • Dermatopathology • Immunology • Urticaria
http://www.ncbi.nlm.nih.gov/pubmed/31446134
 
Aug 26, 2019
 
Prev Next